Page last updated: 2024-10-27

vanoxerine and Parkinson Disease

vanoxerine has been researched along with Parkinson Disease in 2 studies

vanoxerine: structure given in first source
vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stopper, H1
Schupp, N1
Fazeli, G1
Dietel, B1
Queisser, N1
Walitza, S1
Gerlach, M1
Ding, YS1
Fowler, JS1
Volkow, ND1
Gatley, SJ1
Logan, J1
Dewey, SL1
Alexoff, D1
Fazzini, E1
Wolf, AP1

Other Studies

2 other studies available for vanoxerine and Parkinson Disease

ArticleYear
Genotoxicity of the neurotransmitter dopamine in vitro.
    Toxicology in vitro : an international journal published in association with BIBRA, 2009, Volume: 23, Issue:4

    Topics: Animals; Antioxidants; Apoptosis; Cells, Cultured; Dopamine; Humans; Micronucleus Tests; Mutagenicit

2009
Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron.
    Synapse (New York, N.Y.), 1994, Volume: 18, Issue:2

    Topics: Aged; Animals; Chromatography, High Pressure Liquid; Dopamine; Dopamine Uptake Inhibitors; Female; H

1994